Omnicell, Inc. (OMCL) Stock Analysis and Metrics

Sector: Healthcare Industry: Health Information Services CIK: 0000926326

Market Cap 1.99 Bn

P/E 858.13

P/S 1.68

Div. Yield 0.00

ROIC (Qtr) 0.00

Revenue Growth (1y) (Qtr) 2.32

Add ratio to table...

About

Omnicell, Inc., a prominent player in the healthcare industry, is dedicated to resolving the complex challenges associated with medication management and elevating the role of healthcare professionals in patient care delivery. The company's primary focus is on equipping and empowering pharmacists and nurses to prioritize patient care over administrative tasks, thereby driving improved clinical, operational, and financial outcomes across various care settings. Omnicell's diverse range of products and services cater to the evolving continuum of care,...

Omnicell, Inc., a prominent player in the healthcare industry, is dedicated to resolving the complex challenges associated with medication management and elevating the role of healthcare professionals in patient care delivery. The company's primary focus is on equipping and empowering pharmacists and nurses to prioritize patient care over administrative tasks, thereby driving improved clinical, operational, and financial outcomes across various care settings.

Omnicell's diverse range of products and services cater to the evolving continuum of care, encompassing inpatient, outpatient, and retail settings. Its solutions are designed to enhance pharmacy operations, patient adherence, and clinical outcomes, while simultaneously reducing costs and improving patient safety. The company's main business activities include point of care automation, central pharmacy automation, specialty pharmacy, and retail pharmacy.

Point of care automation solutions from Omnicell are engineered to streamline clinician workflows in patient care areas of the healthcare system. Central pharmacy automation solutions, on the other hand, optimize medication dispensing and intravenous (IV) compounding operations. The company's specialty pharmacy services offering comprises a comprehensive set of technology, services, and expertise, providing a fully managed in-house specialty pharmacy delivered through a value-based commercial model. Retail pharmacy solutions are designed to improve pharmacy operations, patient adherence, and clinical outcomes, while also reducing costs and enhancing patient safety.

Omnicell's position within the industry is robust, with the company recognized as a leader in medication management and pharmacy automation. Key competitors include other providers of pharmacy automation and technology solutions. Omnicell's competitive advantages include its extensive portfolio of products and services, expertise in medication management and pharmacy automation, and the ability to deliver integrated solutions that address the evolving needs of healthcare institutions.

Healthcare institutions, pharmacies, and other organizations utilizing Omnicell's products and services aim to improve pharmacy operations, patient adherence, and clinical outcomes. The company's customer base includes a diverse range of organizations, such as acute care hospitals, long-term care facilities, retail pharmacies, and specialty pharmacies.

In terms of brand names and trade names, Omnicell's offerings include point of care automation solutions like XT Series Automated Medication Dispensing Systems, central pharmacy automation solutions like central pharmacy robotic systems, and retail pharmacy solutions like the OmnicellÂ® Medication Adherence Packaging System. The company's specialty pharmacy services encompass a wide range of technology, services, and expertise, while its point of care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system.

Regulatory compliance is a critical aspect of Omnicell's business, with the company subject to various laws and regulations governing its operations. These include the Federal Food, Drug, and Cosmetic Act, the Controlled Substances Act, the Anti-Kickback Statute, the False Claims Act, the Stark Law, and the Physician Payments Sunshine Act. Additionally, Omnicell is subject to trade regulations, such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, as well as various state and local laws and regulations.

Omnicell's manufacturing process for its automation products allows the company to uniquely configure hardware and software to meet a wide variety of individual customer needs. The medication adherence product manufacturing process consists of fabrication and assembly of equipment and mechanized process manufacturing of consumables. Omnicell relies on a limited number of suppliers for the raw materials necessary in the production of its consumable medication packages.

The company's environmental, social, and governance (ESG) initiatives promote a culture of sustainability, diversity, equity, and inclusion. Omnicell views itself as a purpose-driven company with a social mission to fundamentally transform the pharmacy care delivery model and improve health outcomes and lower healthcare costs for everyone. The company's ESG initiatives include reducing greenhouse gas emissions, promoting diversity and inclusion, and improving employee engagement and well-being.

Human capital management is a key focus for Omnicell, with a strong emphasis on employee development and retention. The company offers a comprehensive wellness program, employee development opportunities, and a competitive compensation and benefits package. Omnicell's diverse and inclusive culture, coupled with its commitment to diversity, equity, and inclusion, contributes to its strong employee engagement survey scores, which surpass industry benchmarks.

Investment thesis

Bull case

Omnicell’s transition to a subscription‑centric business model is materialized through the Omnisphere platform, which now underpins a growing suite of connected devices, including the newly launched Titan XT. The company’s guidance for 2026—projecting ARR in the $680‑$700 million range and product bookings between $510‑$560 million—reflects a strong shift from capital‑intensive hardware to recurring revenue streams that will drive predictable cash flows. By integrating cloud‑based analytics and AI‑enabled decision support, Omnicell positions itself as a strategic partner for health systems seeking to reduce medication errors and streamline supply chains, thereby enhancing the value proposition beyond mere device sales. Early wins at large academic and integrated networks, coupled with the ability to service both pharmacy and nursing domains, create a compelling multi‑vertical moat that the market has not yet fully priced in. Consequently, the company’s growth prospects are likely to outpace current consensus estimates, especially as the adoption curve for Titan XT unfolds over the next five to seven years.
The backlog of $640 million, only 1 % lower than 2024, signals a robust pipeline that remains largely insulated from the downturn in product bookings caused by the XT refresh cycle. Most of the short‑term backlog—$435 million—is expected to convert into revenue in 2026, while the long‑term portion, $205 million, represents new opportunities that may unlock additional service contracts and consumables sales once Titan XT is fully deployed. Importantly, the company’s recent launch of the Titan XT at the ASHP event generated enthusiastic engagement from over 4,000 pharmacy leaders, indicating strong demand for an enterprise‑wide automation solution that is not yet offered by competitors. The early traction suggests that the market may soon experience a “product‑refresh boom,” providing Omnicell with a significant upside as the hardware lifecycle of existing XT installations matures. This momentum, combined with the company’s high‑trust CSF I certification and the continued rollout of Omnisphere, supports a bullish outlook that capitalizes on untapped customer adoption potential.
Omnicell’s strategic financing initiatives—particularly the introduction of an Omnicell‑financed leasing program—address a long‑standing barrier for hospitals that have historically relied on third‑party leases. By offering an integrated lease solution, the company can win competitive bids that were previously inaccessible, especially against rivals that do not provide a comparable financing structure. The CFO’s emphasis on investing in sales force expansion and clinical education further reinforces the company’s capability to close larger deals, potentially converting a higher percentage of initial hardware sales into recurring service contracts. This dual focus on hardware deployment and post‑sales revenue growth creates a virtuous cycle that not only improves top‑line revenue but also enhances margin stability over the long term. The incremental investment in sales and clinical enablement, though capital‑intensive in the short run, is poised to yield high returns as the company captures a greater share of the autonomous medication management market.
The regulatory landscape and data security environment work favorably for Omnicell. Achieving high‑trust CSF I certification in 2025 demonstrates the company’s compliance with stringent cybersecurity and privacy standards, mitigating potential regulatory risks and building credibility with health‑system decision makers. As the healthcare industry increasingly adopts AI‑driven workflows, Omnicell’s cloud‑native architecture positions it to incorporate emerging technologies such as generative AI without additional infrastructure overhead, offering a clear competitive advantage. The company’s consistent investment in platform intelligence, evidenced by the Omnisphere upgrade roadmap, signals a long‑term commitment to technological leadership that can drive cost efficiencies for customers while opening new revenue streams. In a sector where data breaches can lead to significant reputational damage and regulatory scrutiny, Omnicell’s proactive approach to security and compliance enhances its value proposition and may translate into premium pricing and stronger customer retention.
From a financial standpoint, Omnicell has effectively managed its balance sheet, paying off $175 million in debt and repurchasing $78 million of common stock in 2025, which has reduced interest burden and improved leverage ratios. Despite the recent dip in non‑GAAP gross margin—from 47.4 % in 2024 to 43.2 % in 2025—cash flow remains robust, with free cash flow of $18 million in Q4 2025 and an annualized $75 million in 2025, indicating sufficient liquidity to fund platform development and sales expansion. The company’s projected 2026 EBITDA range of $145‑$160 million, coupled with a strong recurring revenue mix, suggests that margin erosion can be mitigated through the scalability of software services and the eventual realization of higher‑margin service contracts. Moreover, the planned ERP upgrade and associated $10 million expense in 2026 are positioned as strategic investments that will modernize back‑office operations and reduce future operational costs. Taken together, these financial metrics point to a resilient business model that can sustain growth while maintaining a healthy cash position.

Omnicell’s transition to a subscription‑centric business model is materialized through the Omnisphere platform, which now underpins a growing suite of connected devices, including the newly launched Titan XT. The company’s guidance for 2026—projecting ARR in the $680‑$700 million range and product bookings between $510‑$560 million—reflects a strong shift from capital‑intensive hardware to recurring revenue streams that will drive predictable cash flows. By integrating cloud‑based analytics and AI‑enabled decision support, Omnicell positions itself as a strategic partner for health systems seeking to reduce medication errors and streamline supply chains, thereby enhancing the value proposition beyond mere device sales. Early wins at large academic and integrated networks, coupled with the ability to service both pharmacy and nursing domains, create a compelling multi‑vertical moat that the market has not yet fully priced in. Consequently, the company’s growth prospects are likely to outpace current consensus estimates, especially as the adoption curve for Titan XT unfolds over the next five to seven years.
The backlog of $640 million, only 1 % lower than 2024, signals a robust pipeline that remains largely insulated from the downturn in product bookings caused by the XT refresh cycle. Most of the short‑term backlog—$435 million—is expected to convert into revenue in 2026, while the long‑term portion, $205 million, represents new opportunities that may unlock additional service contracts and consumables sales once Titan XT is fully deployed. Importantly, the company’s recent launch of the Titan XT at the ASHP event generated enthusiastic engagement from over 4,000 pharmacy leaders, indicating strong demand for an enterprise‑wide automation solution that is not yet offered by competitors. The early traction suggests that the market may soon experience a “product‑refresh boom,” providing Omnicell with a significant upside as the hardware lifecycle of existing XT installations matures. This momentum, combined with the company’s high‑trust CSF I certification and the continued rollout of Omnisphere, supports a bullish outlook that capitalizes on untapped customer adoption potential.
Omnicell’s strategic financing initiatives—particularly the introduction of an Omnicell‑financed leasing program—address a long‑standing barrier for hospitals that have historically relied on third‑party leases. By offering an integrated lease solution, the company can win competitive bids that were previously inaccessible, especially against rivals that do not provide a comparable financing structure. The CFO’s emphasis on investing in sales force expansion and clinical education further reinforces the company’s capability to close larger deals, potentially converting a higher percentage of initial hardware sales into recurring service contracts. This dual focus on hardware deployment and post‑sales revenue growth creates a virtuous cycle that not only improves top‑line revenue but also enhances margin stability over the long term. The incremental investment in sales and clinical enablement, though capital‑intensive in the short run, is poised to yield high returns as the company captures a greater share of the autonomous medication management market.
The regulatory landscape and data security environment work favorably for Omnicell. Achieving high‑trust CSF I certification in 2025 demonstrates the company’s compliance with stringent cybersecurity and privacy standards, mitigating potential regulatory risks and building credibility with health‑system decision makers. As the healthcare industry increasingly adopts AI‑driven workflows, Omnicell’s cloud‑native architecture positions it to incorporate emerging technologies such as generative AI without additional infrastructure overhead, offering a clear competitive advantage. The company’s consistent investment in platform intelligence, evidenced by the Omnisphere upgrade roadmap, signals a long‑term commitment to technological leadership that can drive cost efficiencies for customers while opening new revenue streams. In a sector where data breaches can lead to significant reputational damage and regulatory scrutiny, Omnicell’s proactive approach to security and compliance enhances its value proposition and may translate into premium pricing and stronger customer retention.
From a financial standpoint, Omnicell has effectively managed its balance sheet, paying off $175 million in debt and repurchasing $78 million of common stock in 2025, which has reduced interest burden and improved leverage ratios. Despite the recent dip in non‑GAAP gross margin—from 47.4 % in 2024 to 43.2 % in 2025—cash flow remains robust, with free cash flow of $18 million in Q4 2025 and an annualized $75 million in 2025, indicating sufficient liquidity to fund platform development and sales expansion. The company’s projected 2026 EBITDA range of $145‑$160 million, coupled with a strong recurring revenue mix, suggests that margin erosion can be mitigated through the scalability of software services and the eventual realization of higher‑margin service contracts. Moreover, the planned ERP upgrade and associated $10 million expense in 2026 are positioned as strategic investments that will modernize back‑office operations and reduce future operational costs. Taken together, these financial metrics point to a resilient business model that can sustain growth while maintaining a healthy cash position.

Bear case

Omnicell’s non‑GAAP gross margin has slipped from 47.4 % in 2024 to 43.2 % in 2025, a decline driven by tariff costs and a shift in product mix toward lower‑margin items. The Q4 2025 report highlighted a $7 million tariff expense and a 1 % product margin decline, underscoring the company’s exposure to fluctuating trade policy and commodity price volatility. If tariffs increase or if the company continues to ship a higher proportion of lower‑margin devices, the gross margin erosion could become permanent, eroding the operating leverage that the company has built around high‑margin services. Investors should be wary that the guidance for 2026 still incorporates an estimated $15 million tariff impact, suggesting that margin compression may persist even as the company grows its recurring revenue base. This structural risk could limit the upside of the subscription model if operating costs continue to rise.
The capital intensity of Omnicell’s product development and market expansion strategy is evident in the significant operating expenses reported. Research and development costs increased from $26 million in 2024 to $22 million in Q4 2025, while sales, general, and administrative expenses rose from $103 million to $107 million, reflecting aggressive investment in sales force, clinical enablement, and technology upgrades. The planned $10 million ERP upgrade in 2026 further adds to the expense burden. While these investments are aimed at driving future growth, they also raise concerns about cost overruns, especially given the company’s history of restructuring charges and restructuring expenses in the EnlivenHealth and 340B segments. Should the anticipated revenue gains from these initiatives fail to materialize, the company could face cash flow constraints and reduced profitability.
Omnicell’s competitive environment is tightening as rivals introduce their own platform‑centric automation solutions. Management’s acknowledgment of a “competitive convergence” in 2025 indicates that large health systems are evaluating multiple vendors, and the company’s current advantage may be eroded if competitors secure similar or better pricing, financing, or integration capabilities. The company’s reliance on a flagship product, the XT line, that is approaching the end of its lifecycle, makes it vulnerable to market share loss if competitors deliver comparable functionality at lower cost or with earlier deployment timelines. The Q&A session revealed uncertainty around the adoption pace of Titan XT, with some customers expressing hesitation due to the need for full system refreshes and the lack of current hardware upgrades in their facilities. In a commoditized market, even small pricing or service advantages can tip the balance, potentially leading to margin pressure for Omnicell.
The transition from XT to Titan XT introduces significant operational risks that management has not fully addressed. While the Titan XT launch was positioned as a next‑generation solution, the company admitted that no orders had been placed for Titan XT in 2025, implying a delayed revenue conversion. The reliance on a long‑term hardware replacement cycle—estimated at over $2.5 billion—assumes that health systems will commit to a capital investment that may be postponed or cancelled due to budget constraints, especially in the face of economic uncertainty and shifting reimbursement models. Additionally, the company’s acknowledgment of a "bell curve" adoption pattern indicates that revenue will peak only after a multi‑year rollout, leaving the company exposed to long periods of low incremental revenue before the full hardware refresh opportunity materializes. These uncertainties, combined with the potential for lower-than‑expected adoption, pose a serious risk to projected growth trajectories.
Regulatory, cyber, and supply‑chain risks present another layer of vulnerability for Omnicell. The company’s disclosure of a $7 million tariff impact in 2025 and a $15 million estimate for 2026 illustrates sensitivity to trade policy, which could worsen if tariff regimes tighten or if the company encounters new import restrictions. Moreover, the healthcare sector’s heightened focus on data privacy and security, coupled with recent ransomware incidents across the industry, creates a scenario where any breach of Omnicell’s cloud platform could lead to significant legal liability, regulatory penalties, and reputational damage. The company’s reliance on a limited number of component suppliers for critical hardware also exposes it to supply‑chain disruptions that could delay product delivery or inflate costs. These intertwined risks could erode customer confidence and delay product deployment, directly impacting revenue and margin profiles.

Omnicell’s non‑GAAP gross margin has slipped from 47.4 % in 2024 to 43.2 % in 2025, a decline driven by tariff costs and a shift in product mix toward lower‑margin items. The Q4 2025 report highlighted a $7 million tariff expense and a 1 % product margin decline, underscoring the company’s exposure to fluctuating trade policy and commodity price volatility. If tariffs increase or if the company continues to ship a higher proportion of lower‑margin devices, the gross margin erosion could become permanent, eroding the operating leverage that the company has built around high‑margin services. Investors should be wary that the guidance for 2026 still incorporates an estimated $15 million tariff impact, suggesting that margin compression may persist even as the company grows its recurring revenue base. This structural risk could limit the upside of the subscription model if operating costs continue to rise.
The capital intensity of Omnicell’s product development and market expansion strategy is evident in the significant operating expenses reported. Research and development costs increased from $26 million in 2024 to $22 million in Q4 2025, while sales, general, and administrative expenses rose from $103 million to $107 million, reflecting aggressive investment in sales force, clinical enablement, and technology upgrades. The planned $10 million ERP upgrade in 2026 further adds to the expense burden. While these investments are aimed at driving future growth, they also raise concerns about cost overruns, especially given the company’s history of restructuring charges and restructuring expenses in the EnlivenHealth and 340B segments. Should the anticipated revenue gains from these initiatives fail to materialize, the company could face cash flow constraints and reduced profitability.
Omnicell’s competitive environment is tightening as rivals introduce their own platform‑centric automation solutions. Management’s acknowledgment of a “competitive convergence” in 2025 indicates that large health systems are evaluating multiple vendors, and the company’s current advantage may be eroded if competitors secure similar or better pricing, financing, or integration capabilities. The company’s reliance on a flagship product, the XT line, that is approaching the end of its lifecycle, makes it vulnerable to market share loss if competitors deliver comparable functionality at lower cost or with earlier deployment timelines. The Q&A session revealed uncertainty around the adoption pace of Titan XT, with some customers expressing hesitation due to the need for full system refreshes and the lack of current hardware upgrades in their facilities. In a commoditized market, even small pricing or service advantages can tip the balance, potentially leading to margin pressure for Omnicell.
The transition from XT to Titan XT introduces significant operational risks that management has not fully addressed. While the Titan XT launch was positioned as a next‑generation solution, the company admitted that no orders had been placed for Titan XT in 2025, implying a delayed revenue conversion. The reliance on a long‑term hardware replacement cycle—estimated at over $2.5 billion—assumes that health systems will commit to a capital investment that may be postponed or cancelled due to budget constraints, especially in the face of economic uncertainty and shifting reimbursement models. Additionally, the company’s acknowledgment of a "bell curve" adoption pattern indicates that revenue will peak only after a multi‑year rollout, leaving the company exposed to long periods of low incremental revenue before the full hardware refresh opportunity materializes. These uncertainties, combined with the potential for lower-than‑expected adoption, pose a serious risk to projected growth trajectories.
Regulatory, cyber, and supply‑chain risks present another layer of vulnerability for Omnicell. The company’s disclosure of a $7 million tariff impact in 2025 and a $15 million estimate for 2026 illustrates sensitivity to trade policy, which could worsen if tariff regimes tighten or if the company encounters new import restrictions. Moreover, the healthcare sector’s heightened focus on data privacy and security, coupled with recent ransomware incidents across the industry, creates a scenario where any breach of Omnicell’s cloud platform could lead to significant legal liability, regulatory penalties, and reputational damage. The company’s reliance on a limited number of component suppliers for critical hardware also exposes it to supply‑chain disruptions that could delay product delivery or inflate costs. These intertwined risks could erode customer confidence and delay product deployment, directly impacting revenue and margin profiles.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEHC	GE HealthCare Technologies Inc.	33.68 Bn	16.10	1.63	10.00 Bn
2	VEEV	Veeva Systems Inc	24.74 Bn	27.17	7.74	-
3	BTSG	BrightSpring Health Services, Inc.	8.67 Bn	47.49	0.67	2.51 Bn
4	HQY	Healthequity, Inc.	6.68 Bn	31.57	5.09	0.96 Bn
5	WAY	Waystar Holding Corp.	4.08 Bn	33.31	3.72	1.47 Bn
6	DOCS	Doximity, Inc.	3.87 Bn	16.48	6.07	-
7	TXG	10x Genomics, Inc.	2.96 Bn	-66.16	4.60	-
8	PRVA	Privia Health Group, Inc.	2.77 Bn	117.89	1.30	-

Research Tools

Omnicell, Inc. (NASDAQ: OMCL)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Omnicell, Inc. (NASDAQ: OMCL)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password